Colistin
Active ingredient · 2 therapeutic classes
Sold as COLY-MYCIN M
- Drug class
- Antibiotics
- Availability
- See label
- Routes
- Intramuscular, Intravenous
- Markets covered
- 1
- Products on record
- 3
Overview
Colistin is an active pharmaceutical ingredient in the Antibiotics group (A07AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 3 | March 22, 2025 |
CACanada· Health Canada
3 products
Uses
) is indicated for: • the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. Particularly indicated when the infection is caused by sensitive strains of P. aeruginosa. This antibiotic is not indicated for infections due to proteus or neisseria.
Sodium colistimethate has proven clinically effective in treatment of infections due to the following gram-negative organisms: A. aerogenes, E. coli, K. pneumoniae and P. aeruginosa. Pending results of appropriate bacteriologic cultures and sensitivity tests, sodium colistimethate may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of COLY-MYCIN M and other antibacterial drugs, COLY-MYCIN M should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
Sources & citations
- [1]Health Canada (DPD) · 00476420 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.